Abbott, GSK to develop molecular lung cancer test
Abbott has entered into an agreement with GlaxoSmithKline (GSK) to develop an automated molecular diagnostic test, based on polymerase chain reaction (PCR) technology, intended to screen non-small cell lung cancer tumors for expression of the MAGE-A3 antigen.
The London-based GSK said that MAGE-A3 Antigen Specific Cancer Immunotherapy (ASCI) candidate is currently being evaluated as an adjuvant treatment in resected non-small cell lung cancer in the phase III clinical study MAGRIT.
Under terms of the agreement, the Abbott Park, Ill.-based Abbott, in conjunction with GSK, will develop and commercialize a PCR test designed to detect MAGE A3 for use on the Abbott m2000 automated instrument system.
Currently, there are no FDA-approved nucleic acid-based tests for use in identifying patients who may derive treatment benefits from targeted non-small cell lung cancer therapies, according to the companies.
The London-based GSK said that MAGE-A3 Antigen Specific Cancer Immunotherapy (ASCI) candidate is currently being evaluated as an adjuvant treatment in resected non-small cell lung cancer in the phase III clinical study MAGRIT.
Under terms of the agreement, the Abbott Park, Ill.-based Abbott, in conjunction with GSK, will develop and commercialize a PCR test designed to detect MAGE A3 for use on the Abbott m2000 automated instrument system.
Currently, there are no FDA-approved nucleic acid-based tests for use in identifying patients who may derive treatment benefits from targeted non-small cell lung cancer therapies, according to the companies.